Trevi Therapeutics’ (TRVI) Buy Rating Reiterated at Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of Trevi Therapeutics (NASDAQ:TRVI) in a research report sent to investors on Friday, AnalystRatings.com reports. Needham & Company LLC currently has a $18.00 price target on the stock.

Separately, Zacks Investment Research upgraded shares of Trevi Therapeutics from a sell rating to a hold rating in a report on Thursday, October 10th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The stock has a consensus rating of Buy and an average price target of $16.75.

Trevi Therapeutics stock traded up $0.30 during mid-day trading on Friday, reaching $4.20. The company had a trading volume of 15,100 shares, compared to its average volume of 17,847. Trevi Therapeutics has a 1 year low of $2.65 and a 1 year high of $10.62. The business’s 50-day simple moving average is $3.86.

Trevi Therapeutics (NASDAQ:TRVI) last announced its earnings results on Thursday, November 14th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.48) by $0.07. On average, research analysts predict that Trevi Therapeutics will post -2.44 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently made changes to their positions in the business. BlackRock Inc. acquired a new position in shares of Trevi Therapeutics in the 2nd quarter valued at $26,000. Morgan Stanley acquired a new position in shares of Trevi Therapeutics in the 2nd quarter valued at $42,000. Northern Trust Corp acquired a new position in shares of Trevi Therapeutics in the 2nd quarter valued at $124,000. Vanguard Group Inc. acquired a new position in shares of Trevi Therapeutics in the 2nd quarter valued at $886,000. Finally, Omega Fund Management LLC acquired a new position in shares of Trevi Therapeutics in the 2nd quarter valued at $9,476,000. Institutional investors own 79.55% of the company’s stock.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. The company's nalbuphine ER, which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease.

Featured Story: Understanding the different types of bonds

Analyst Recommendations for Trevi Therapeutics (NASDAQ:TRVI)

Receive News & Ratings for Trevi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.